Abstract:Objective: Enhanced expression of PAI-1 (plasminogen activator inhibitor-1) has been implicated in atherosclerosis formation in humans with obesity and metabolic syndrome. However, little is known about the effects of pharmacological targeting of PAI-1 on atherogenesis. This study examined the effects of pharmacological PAI-1 inhibition on atherosclerosis formation in a murine model of obesity and metabolic syndrome. Approach and Results: LDL receptor-deficient (ldlr-/-) mice were fed a Western diet high in cholesterol, fat, and sucrose to induce obesity, metabolic dysfunction, and atherosclerosis. Western diet triggered significant upregulation of PAI-1 expression compared with normal diet controls. Addition of a pharmacological PAI-1 inhibitor (either PAI-039 or MDI-2268) to Western diet significantly inhibited obesity and atherosclerosis formation for up to 24 weeks without attenuating food consumption. Pharmacological PAI-1 inhibition significantly decreased macrophage accumulation and cell senescence in atherosclerotic plaques. Recombinant PAI-1 stimulated smooth muscle cell senescence, whereas a PAI-1 mutant defective in LRP1 (LDL receptor-related protein 1) binding did not. The prosenescent effect of PAI-1 was blocked by PAI-039 and R2629, a specific anti-LRP1 antibody. PAI-039 significantly decreased visceral adipose tissue inflammation, hyperglycemia, and hepatic triglyceride content without altering plasma lipid profiles. Conclusions: Pharmacological targeting of PAI-1 inhibits atherosclerosis in mice with obesity and metabolic syndrome, while inhibiting macrophage accumulation and cell senescence in atherosclerotic plaques, as well as obesity-associated metabolic dysfunction. PAI-1 induces senescence of smooth muscle cells in an LRP1-dependent manner. These results help to define the role of PAI-1 in atherosclerosis formation and suggest a new plasma-lipid-independent strategy for inhibiting atherogenesis.

The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo

Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition

A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?

Three Decades of Research on Plasminogen Activator Inhibitor-1: A Multifaceted Serpin

Plasminogen activator inhibitor-1 inhibitors: a patent review (2006 – present)

Past, Present, and Future Perspectives of Plasminogen Activator Inhibitor 1 (PAI-1)

Functional Stability of Plasminogen Activator Inhibitor-1

A Serpin With a Finger in Many PAIs: PAI-1's Central Function in Thromboinflammation and Cardiovascular Disease

Plasminogen Activator Inhibitor 1 (PAI-1) in Plasma: Its Role in Thrombotic Disease

Targeting Plasminogen Activator Inhibitor-1 to Prevent Vascular Disease

Research Progress of Plasminogen Activator Inhibitor-1 in Several Diseases

The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding

Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin

PAI-1 in Diabetes: Pathophysiology and Role as a Therapeutic Target

High-throughput amino acid-level characterization of the interactions of plasminogen activator inhibitor-1 with variably divergent proteases

Drug Targeting of Plasminogen Activator Inhibitor-1 Inhibits Metabolic Dysfunction and Atherosclerosis in a Murine Model of Metabolic Syndrome

Importance of Fibrinolytic Activity in Patients with Coronary Artery Diseases

Good or bad: Paradox of plasminogen activator inhibitor 1 (PAI-1) in digestive system tumors

Structural basis for therapeutic intervention of uPA/uPAR system

The Role of Plasminogen Activator Inhibitor Type-1 in Fibrosis

Genome-wide Association Study for Circulating Levels of Plasminogen Activator Inhibitor-1 (PAI-1) Provides Novel Insights into the Regulation of PAI-1 Running Title: HUANG Et Al., GENETIC LOCI ASSOCIATED WITH PAI-1